📹 Kaio Jorge was clinical as Cruzeiro end Palmeiras' unbeaten run
📹 Kaio Jorge was clinical as Cruzeiro end Palmeiras' unbeaten run
Cruzeiro disregarded Palmeiras' hitherto enviable unbeaten away record this season.
Thanks to the lethal Kaio Jorge, Raposa beat Verdão 2 x 1 this Sunday (1), in a pulsating Mineirão with over 58,000 attendees.
Advertisement
Assuming the vice-leadership of the Brazilian Championship after their 11th game without defeat in 2025.
Didn't have time to blink 🤯
The clock marked four minutes and Cruzeiro was already winning by two goals difference.
Thanks to Kaio Jorge, reinforcing his great moment.
The first came after a corner kick.
Soon after, KJ9 picked up the leftovers in the area to extend the lead.
This changed all the tactics planned by Abel Ferreira.
The most possession before the interval was even Verdão's.
Who only posed a real threat at 43', with Piquerez. And then, with Giay in the stoppage time.
Changes, attempts and +
Abel took out Veiga and Flaco - ensuring the entries of Vitor Roque and Paulinho.
Advertisement
And the dominance was all his team's in the final stage.
Real goal chance? Just one.
Palmeiras had impetus and dedicated themselves.
But only reduced the deficit at 87', when Evangelista activated Allan.
He had space and took it out of Cássio's reach.
The pressure intensified. But the victory was celestial from the relentless Lucas Romero and Silva.
There were 14 wins and three draws in 17 Palmeiras' away games until they faced Cabuloso.
📊 Table and schedule 📅
Cruzeiro went to 23 points. Only sees Flamengo (24) ahead.
Left Palmeiras with 22 and in fourth.
Raposa will still visit Vitória at Barradão before the BR break.
Advertisement
Match of the 12th round that will be played after the Fifa date, on the 12th.
Palmeiras now focuses solely and exclusively on the Super World Club Championship.
They will make their debut on the 15th, when they will face Porto.
They will still face Al-Ahly (19/6) and Inter Miami (23/6) in Group A.
This article was translated into English by Artificial Intelligence. You can read the original version in 🇧🇷 here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business of Fashion
9 minutes ago
- Business of Fashion
Skechers Shareholder Sues Footwear Maker for Details on $9.4 Billion 3G Buyout
A Skechers USA shareholder has sued the footwear maker for more details about its $9.4 billion buyout by private equity firm 3G Capital, saying the decision by Skechers' founder and controlling shareholder to sell raises 'red flags.' According to a complaint filed on Thursday in Los Angeles federal court, founder Robert Greenberg and his family, who hold about 60% of Skechers' voting power, appear to have 'controlled the sales process to a single bidder and deprived the minority stockholders of any legitimate bidding process.' Florida-based Key West Police Officers & Firefighters Retirement Plan said the buyout should not close until Skechers makes required disclosures with the US Securities and Exchange Commission to help shareholders decide if the terms are fair. The complaint cited a Reuters article in which Needham analyst Tom Nikic called the buyout 'very surprising' because Skechers was considered a family business, and sources said the Greenbergs eschewed an auction because of their long ties to 3G. Skechers spokeswoman Jennifer Clay declined to comment on Friday, saying the Manhattan Beach, California-based company does not discuss pending litigation. The vast majority of large US corporate mergers are challenged in court. Lawsuits seeking greater disclosures often end with defendants paying legal fees to plaintiffs' lawyers, and plaintiffs recovering nominal payouts or nothing. According to a regulatory filing, Greenberg, 85, could collect more than $1 billion from the buyout, which is scheduled to close in the third quarter. The buyout values Skechers at $63 per share in cash, 20 percent below its 52-week high of $78.82 set on January 30. Like other footwear makers including Nike, Skechers faces pressure from US President Donald Trump's tariffs. Many Skechers' products come from China, and the company withdrew its full-year financial guidance in April. Brazil-based 3G is known for stringent cost-cutting, including at such companies as Anheuser-Busch InBev and Kraft Heinz. The case is Key West Police Officers & Firefighters Retirement Plan v Skechers USA Inc et al, US District Court, Central District of California, No. 25-04863. By Jonathan Stempel; Editor: Richard Chang Learn more: Skechers' $9.4 Billion Blockbuster Buyout, Explained The comfort sneaker brand's $63-per-share acquisition by the Brazilian private equity firm 3G shocked both the fashion and financial worlds.
Medscape
5 hours ago
- Medscape
Inexpensive HIV Med Improves Vision in Diabetic Eye Disease
Oral lamivudine, an inflammasome inhibitor originally approved for suppressing HIV, was a relatively safe and effective treatment for improving visual acuity in adults with center-involving diabetic macular edema, a serious complication of diabetic retinopathy. METHODOLOGY: Researchers conducted a clinical trial to assess the effectiveness of oral lamivudine vs placebo in improving visual acuity in 24 adults (mean age, 62.7 years; 55% women) with type 2 diabetes and center-involving diabetic macular edema from a tertiary center in São Paulo, Brazil. Best-corrected visual acuity was less than 69 letters in this cohort. The participants were randomly assigned to receive either oral lamivudine (150 mg twice daily; 10 participants; 16 eyes) or placebo (14 participants; 21 eyes) for 8 weeks, with intravitreous bevacizumab (1.25 mg) administered at week 4. Primary outcomes were the mean changes in best-corrected visual acuity from baseline to weeks 4 and 8, and secondary outcomes included changes in retinal thickness and adverse events. Outcomes in the lamivudine group were compared with those in a historical cohort of individuals who received aflibercept, bevacizumab, or ranibizumab. TAKEAWAY: Participants who received lamivudine experienced a significant improvement in visual acuity as early as week 4, with a mean gain of 9.8 letters on the eye chart, whereas those on placebo had a mean loss of 1.8 letters ( P < .001) ; 94% of eyes in the lamivudine group showed an improvement in best-corrected visual acuity compared with just 24% in the placebo group. < .001) ; 94% of eyes in the lamivudine group showed an improvement in best-corrected visual acuity compared with just 24% in the placebo group. Following injection of bevacizumab at week 4, patients in the lamivudine group showed greater improvement in visual acuity than those who received placebo (16.9 vs 5.3 letters; P < .001) at week 8. < .001) at week 8. When compared with drugs in the historical cohort, lamivudine was at least as effective as aflibercept and more effective than bevacizumab or ranibizumab. No significant differences were observed in retinal thickness or adverse events between the lamivudine and placebo groups; no serious systemic adverse events such as lactic acidosis or hepatic or renal toxicity were reported during the study period. IN PRACTICE: Continual intravitreous administration of anti–vascular endothelial growth factor drugs, 'which requires frequent visits to doctors' offices, imposes a substantial burden on patients and healthcare systems,' the researchers reported. 'Repurposing existing drugs such as lamivudine enables potentially immediate translation to practice and could obviate the aforementioned challenges by reducing medication costs and eliminating intravitreous injection costs. Such an oral medication would also avoid the potentially blinding complications of intravitreous injections.' 'These findings open the door to a more accessible and less invasive treatment approach for DME [diabetic macular edema], with the potential to benefit millions of patients globally,' they added. SOURCE: This study was led by Felipe Pereira of the Universidade Federal de São Paulo, São Paulo, Brazil. It was published online on May 27, 2025, in Med . LIMITATIONS: The relatively small number of participants was a major limitation. The 8-week duration of the study — imposed because of safety concerns over lamivudine's potential toxicity — precluded assessment of its long-term efficacy and safety. This study took place at a single center in Brazil and involved participants whose characteristics differed from those from the historical cohort who were based in the United States. DISCLOSURES: This study received support from the Universidade Federal de São Paulo, Latinofarma, the National Institutes of Health, and other sources. Some authors declared receiving consultancy fees, were named as inventors on matter-related patent applications, served as scientific consultants, and had other ties with many sources, including the funding agencies.
Bloomberg
8 hours ago
- Bloomberg
Bolsonaro's Plan to Stage a Trumpian Comeback Might Save Lula's Presidency
Jair Bolsonaro's insistence he can pull off a Donald Trump-like comeback in Brazil's looming election has paralyzed his fervent right-wing movement, effectively blocking the search for a successor to the ineligible former president. Unable to run thanks to an eight-year political ban and facing charges that he attempted a coup after the 2022 vote, Bolsonaro is nevertheless clinging to control over the future of the Brazilian right. Pointing to polls that show him as the strongest candidate, he describes himself as victim of political persecution.
